Roundtable Discussion: Shaping the Future of Combination Radioligand Therapy: Preclinical Perspectives

• Balancing toxicity and efficacy: minimizing radiopharmaceutical dose while enhancing tumor kill
• Timing combination therapies: strategies for preclinical-to-clinical translation
• Selecting patients using biomarkers to match optimal RLT combinations with tumor and TME characteristics

Speakers:

S. Sakura Minami

Vice President, Translational Medicine & Nonclinical Development

Iron Fist Therapeutics